Alkermes (FRA:8AK) Beginning Cash Position: €305 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8AK Alkermes PLC FRA:8AK
64 GF Score
Price €40.14
GF Value €27.41
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Alkermes Beginning Cash Position?

Alkermes FRA:8AK -0.64% 64 Beginning Cash Position is €305 Mil as of Jun. 2026. GuruFocus rates FRA:8AK with a GF Score™ of 64/100 and a GF Value™ of €27.41 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Alkermes's Beginning Cash Position for the quarter that ended in Jun. 2026 was €305 Mil.

Alkermes's quarterly Beginning Cash Position increased from Dec. 2025 (€526 Mil) to Mar. 2026 (€969 Mil) but then declined from Mar. 2026 (€969 Mil) to Jun. 2026 (€305 Mil).

Alkermes's annual Beginning Cash Position increased from Dec. 2023 (€268 Mil) to Dec. 2024 (€437 Mil) but then declined from Dec. 2024 (€437 Mil) to Dec. 2025 (€249 Mil).

Alkermes Beginning Cash Position Related Terms

Alkermes Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Alkermes's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkermes Beginning Cash Position Chart

Alkermes Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 241.57 318.64 268.20 436.88 248.64

Alkermes Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 346.63 444.06 526.45 968.61 305.15
FRA:8AK
64GF Score
Alkermes PLC FRA:8AK
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alkermes Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €305 Mil mean?
Alkermes (FRA:8AK) has a Beginning Cash Position of €305 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Alkermes and its competitors.
Is Alkermes' Beginning Cash Position too high?
Alkermes' current Beginning Cash Position is €305 Mil. Overall, Alkermes has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alkermes' Beginning Cash Position compare to HIMS and LNTH?
Alkermes' Beginning Cash Position of €305 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Alkermes and its competitors. Alkermes's current Beginning Cash Position is €305 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkermes stock overvalued right now?
Based on GuruFocus' analysis, Alkermes (FRA:8AK) is currently considered Significantly Overvalued. The stock's GF Value™ is €27.41, compared to a current price of €40.14 — trading 46.4% above its estimated fair value. The current Beginning Cash Position is €305 Mil. Alkermes' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Alkermes (FRA:8AK), the current Beginning Cash Position is €305 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alkermes (FRA:8AK) Overvalued in 2026?

Based on GuruFocus' analysis, Alkermes stock appears to be overvalued. The current stock price of €40.14 is trading 46.4% above its estimated GF Value™ of €27.41. GuruFocus considers Alkermes to be Significantly Overvalued.

Key valuation signals for FRA:8AK:

  • Beginning Cash Position: €305 Mil
  • GF Value™: €27.41 vs. price of €40.14 (46.4% above fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the FRA:8AK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alkermes Business Description

Other Exchanges ALKS:USA
Address 1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
64GF Score

Get the complete analysis for FRA:8AK

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€40.14
Price
€27.41
GF Value